A groundbreaking clinical study has found that administering stem cells to developing infants affected by spina bifida while undergoing fetal surgery can be a "important advancement" in treating birth defects.
Study Parameters and Security
The US-based trial involved six unborn babies with the 'open' form of spina bifida. Medical teams placed mother's placental stem cells to the surface of the developing neural column while the defect was being closed.
Critically, the regenerative treatment was found to be safe. Doctors verified that the cells did not cause tumors, interfere with wound healing, or block the correction of associated brain abnormalities.
Promising Outcomes
Magnetic resonance imaging performed on the newborns indicated a successful correction of Chiari malformation in each of the babies. This brain structure normalization is closely linked to improved motor skills and quality of life.
"If it makes more children to achieve ambulation who wouldn't have, it may emerge as the conventional approach," said the lead researcher. "The results are extremely promising and pave the way for lots of potential innovative interventions."
Future Implications and Hope
Independent medical specialists proposed that subsequent studies of these noted improvements could herald a "fresh chapter" in in-utero treatment. The potential to improve nerve function impairment occurring during fetal development is viewed as a revolutionary objective.
Especially significant would be better management of urogenital and gastrointestinal outcomes, which are typical difficulties for those diagnosed with this defect.
The Path Forward
Despite this being a first-in-human effort involved a limited number of patients, its confirmed tolerability and hopeful trends provide a strong foundation for broader investigative efforts. The combination of regenerative medicine with proven prenatal surgical methods offers substantial hope for transforming outcomes for infants diagnosed prenatally with myelomeningocele.